CN105555787B - 二氮杂二环辛烷衍生物的制备方法及其中间体 - Google Patents

二氮杂二环辛烷衍生物的制备方法及其中间体 Download PDF

Info

Publication number
CN105555787B
CN105555787B CN201480052097.9A CN201480052097A CN105555787B CN 105555787 B CN105555787 B CN 105555787B CN 201480052097 A CN201480052097 A CN 201480052097A CN 105555787 B CN105555787 B CN 105555787B
Authority
CN
China
Prior art keywords
benzyloxy
amino
tert
formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480052097.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN105555787A (zh
Inventor
阿部隆夫
古内刚
坂卷仪晃
三桥那佳子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meiji Seika Pharma Co Ltd
Original Assignee
Meiji Seika Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Pharma Co Ltd filed Critical Meiji Seika Pharma Co Ltd
Priority to CN201710665418.8A priority Critical patent/CN107501264A/zh
Publication of CN105555787A publication Critical patent/CN105555787A/zh
Application granted granted Critical
Publication of CN105555787B publication Critical patent/CN105555787B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)
CN201480052097.9A 2013-09-24 2014-09-24 二氮杂二环辛烷衍生物的制备方法及其中间体 Active CN105555787B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710665418.8A CN107501264A (zh) 2013-09-24 2014-09-24 二氮杂二环辛烷衍生物的制备方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013197110 2013-09-24
JP2013-197110 2013-09-24
PCT/JP2014/075203 WO2015046207A1 (ja) 2013-09-24 2014-09-24 ジアザビシクロオクタン誘導体の製造法とその中間体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710665418.8A Division CN107501264A (zh) 2013-09-24 2014-09-24 二氮杂二环辛烷衍生物的制备方法

Publications (2)

Publication Number Publication Date
CN105555787A CN105555787A (zh) 2016-05-04
CN105555787B true CN105555787B (zh) 2017-08-08

Family

ID=52743343

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480052097.9A Active CN105555787B (zh) 2013-09-24 2014-09-24 二氮杂二环辛烷衍生物的制备方法及其中间体
CN201710665418.8A Pending CN107501264A (zh) 2013-09-24 2014-09-24 二氮杂二环辛烷衍生物的制备方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710665418.8A Pending CN107501264A (zh) 2013-09-24 2014-09-24 二氮杂二环辛烷衍生物的制备方法

Country Status (22)

Country Link
US (2) US10000491B2 (cg-RX-API-DMAC7.html)
EP (1) EP3050883B1 (cg-RX-API-DMAC7.html)
JP (1) JP6453222B2 (cg-RX-API-DMAC7.html)
KR (1) KR102239725B1 (cg-RX-API-DMAC7.html)
CN (2) CN105555787B (cg-RX-API-DMAC7.html)
AR (5) AR097744A1 (cg-RX-API-DMAC7.html)
AU (1) AU2014324302B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016006246B8 (cg-RX-API-DMAC7.html)
CA (1) CA2924953C (cg-RX-API-DMAC7.html)
DK (1) DK3050883T3 (cg-RX-API-DMAC7.html)
ES (1) ES2793201T3 (cg-RX-API-DMAC7.html)
HK (1) HK1244487A1 (cg-RX-API-DMAC7.html)
HU (1) HUE049027T2 (cg-RX-API-DMAC7.html)
IL (1) IL244740B (cg-RX-API-DMAC7.html)
MX (2) MX372585B (cg-RX-API-DMAC7.html)
MY (2) MY176278A (cg-RX-API-DMAC7.html)
NZ (1) NZ718009A (cg-RX-API-DMAC7.html)
RU (1) RU2719480C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201602256UA (cg-RX-API-DMAC7.html)
TW (1) TWI644908B (cg-RX-API-DMAC7.html)
WO (1) WO2015046207A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201602053B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE046893T2 (hu) 2012-05-30 2020-04-28 Meiji Seika Pharma Co Ltd Új ß-laktamáz inhibitor és eljárás elõállítására
DK3050883T3 (da) 2013-09-24 2020-05-25 Meiji Seika Pharma Co Ltd Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter
CN105612159A (zh) * 2013-10-08 2016-05-25 明治制果药业株式会社 二氮杂二环辛烷衍生物的结晶及其制备方法
SG11201704576SA (en) 2014-12-05 2017-07-28 Meiji Seika Pharma Co Ltd Method for producing crystals of diazabicyclooctane derivative and stable lyophilized preparation
CA2944306C (en) 2015-10-30 2023-11-14 The Toronto-Dominion Bank Validating encrypted data from a multi-layer token
US11216808B2 (en) 2015-11-04 2022-01-04 The Toronto-Dominion Bank Token-based system for excising data from databases
JP2020011901A (ja) * 2016-10-20 2020-01-23 協和キリン株式会社 ピロリジン化合物の製造方法
CN106699756B (zh) * 2016-12-30 2019-10-29 淄博鑫泉医药技术服务有限公司 β内酰胺酶抑制剂阿维巴坦的合成方法
KR20200091395A (ko) 2017-09-27 2020-07-30 페도라 파마슈티칼스 인코포레이티드 디아자비시클로옥탄 유도체의 결정형 및 그의 제조 방법
EP3687504B1 (en) 2017-09-27 2024-11-27 Meiji Seika Pharma Co., Ltd. Pharmaceutical forms of diazabicyclooctane derivatives and process for producing the same
TW201920174A (zh) 2017-09-27 2019-06-01 瑞士商羅氏大藥廠股份有限公司 二氮雜雙環辛烷衍生物之醫藥形式及其製法
CN109678856B (zh) * 2017-10-18 2020-09-25 新发药业有限公司 一种阿维巴坦中间体的制备方法
JP7289836B2 (ja) 2017-11-23 2023-06-12 エフ. ホフマン-ラ ロシュ アーゲー プロリンヒドロキシラーゼ、ならびにそれに伴う使用、方法および生成物
US11957690B2 (en) 2018-07-16 2024-04-16 Brown University Chromogenic beta-lactamase substrate
CN119707784A (zh) * 2018-09-21 2025-03-28 株式会社Api 氨基酸衍生物的制备方法
US12195755B2 (en) 2019-05-20 2025-01-14 Brown University Placental lipid bilayer for cell-free molecular interaction studies
WO2021038403A1 (en) 2019-08-30 2021-03-04 DePuy Synthes Products, Inc. Electrical device for monitoring, prevention, and treatment of implant infections
WO2021087008A1 (en) 2019-10-28 2021-05-06 Brown University Bacterial beta-lactamase responsive hydrogels
CN121021508B (zh) * 2025-10-29 2026-02-24 北京耀诚惠仁科技有限公司 β-内酰胺酶抑制剂中间体共晶或盐及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010126820A2 (en) * 2009-04-30 2010-11-04 Merck Sharp & Dohme Corp. Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
WO2011042560A1 (en) * 2009-10-09 2011-04-14 Novexel Sa Polymorphic and pseudopolymorphic forms of a pharmaceutical compound
WO2012086241A1 (ja) * 2010-12-22 2012-06-28 Meiji Seikaファルマ株式会社 光学活性なジアザビシクロオクタン誘導体およびその製造法
WO2012172368A1 (en) * 2011-06-17 2012-12-20 Astrazeneca Ab Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5038509B1 (cg-RX-API-DMAC7.html) 1970-10-21 1975-12-10
JPS538509A (en) 1976-07-13 1978-01-26 Toshiba Corp Impedance matching system for data transmission circuit
GB1589317A (en) 1977-11-24 1981-05-13 Lilly Co Eli Freeze drying cephalothin sodium
JPS6019759B2 (ja) 1977-11-24 1985-05-17 イ−ライ・リリ−・アンド・カンパニ− 非経口投予用11115152139199東京都中央区京橋2丁目3番13号
JPS60255723A (ja) 1984-05-31 1985-12-17 Ono Pharmaceut Co Ltd メシル酸ガベキサートの結晶性凍結乾燥製剤及びその製造方法
JPH07117533B2 (ja) 1985-08-28 1995-12-18 株式会社生体科学研究所 トランスフエリンおよびその用途
US20030220521A1 (en) 1989-07-27 2003-11-27 G.D. Searle & Co. Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension
TW264475B (cg-RX-API-DMAC7.html) 1991-09-20 1995-12-01 Takeda Pharm Industry Co Ltd
ATE177099T1 (de) * 1993-12-29 1999-03-15 Pfizer Diazabicyclische neurokinin antagonisten
JP2843444B2 (ja) 1994-05-02 1999-01-06 塩野義製薬株式会社 ピロリジルチオカルバペネム誘導体の結晶,該結晶を含む凍結乾燥製剤,およびその製造方法
US6111098A (en) 1994-05-02 2000-08-29 Shionogi & Co., Ltd. Crystal of pyrrolidylthiocarbapenem derivative, lyophilized preparation containing said crystal, and process for producing the same
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2815420B1 (fr) 2000-10-16 2003-05-16 Cit Alcatel Compensation de la dispersion chromatique dans un systeme de transmission a fibre optique, et fibre de compensation
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2921060B1 (fr) 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
JP5038509B2 (ja) 2008-01-18 2012-10-03 メルク・シャープ・エンド・ドーム・コーポレイション β−ラクタマーゼ阻害剤
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
JP2012122603A (ja) 2010-11-15 2012-06-28 Nifco Inc コネクタ装置
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
BR112013028813B1 (pt) 2011-08-27 2020-10-20 Wockhardt Limited derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e composições farmacêuticas que os compreendem
CN103649088B (zh) 2011-08-30 2016-05-11 沃克哈特有限公司 1, 6- 二氮杂双环[3, 2, 1]辛- 7- 酮衍生物及其在治疗细菌感染中的用途
BR112014003476A2 (pt) 2011-09-13 2017-03-01 Wockhardt Ltd compostos contendo nitrogênio e seu uso
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
HUE046893T2 (hu) 2012-05-30 2020-04-28 Meiji Seika Pharma Co Ltd Új ß-laktamáz inhibitor és eljárás elõállítására
DK3050883T3 (da) 2013-09-24 2020-05-25 Meiji Seika Pharma Co Ltd Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter
CN105612159A (zh) * 2013-10-08 2016-05-25 明治制果药业株式会社 二氮杂二环辛烷衍生物的结晶及其制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010126820A2 (en) * 2009-04-30 2010-11-04 Merck Sharp & Dohme Corp. Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
WO2011042560A1 (en) * 2009-10-09 2011-04-14 Novexel Sa Polymorphic and pseudopolymorphic forms of a pharmaceutical compound
WO2012086241A1 (ja) * 2010-12-22 2012-06-28 Meiji Seikaファルマ株式会社 光学活性なジアザビシクロオクタン誘導体およびその製造法
WO2012172368A1 (en) * 2011-06-17 2012-12-20 Astrazeneca Ab Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof

Also Published As

Publication number Publication date
IL244740A0 (en) 2016-04-21
US20170283415A1 (en) 2017-10-05
AR131189A2 (es) 2025-02-26
TWI644908B (zh) 2018-12-21
JP6453222B2 (ja) 2019-01-16
MX2016003867A (es) 2016-08-04
EP3050883A4 (en) 2017-05-10
AU2014324302A1 (en) 2016-05-12
BR112016006246B8 (pt) 2021-10-05
BR112016006246A2 (cg-RX-API-DMAC7.html) 2017-08-22
AR131188A2 (es) 2025-02-26
RU2719480C2 (ru) 2020-04-17
MY176278A (en) 2020-07-27
ES2793201T3 (es) 2020-11-13
HK1244487A1 (zh) 2018-08-10
HUE049027T2 (hu) 2020-08-28
IL244740B (en) 2018-11-29
HK1219473A1 (zh) 2017-04-07
AR131186A2 (es) 2025-02-26
RU2016115767A (ru) 2017-10-26
AU2014324302B2 (en) 2018-02-15
DK3050883T3 (da) 2020-05-25
ZA201602053B (en) 2019-06-26
MY193210A (en) 2022-09-26
SG11201602256UA (en) 2016-04-28
BR112016006246B1 (pt) 2021-09-08
EP3050883A1 (en) 2016-08-03
CA2924953C (en) 2021-12-07
CN105555787A (zh) 2016-05-04
CN107501264A (zh) 2017-12-22
AR097744A1 (es) 2016-04-13
CA2924953A1 (en) 2015-04-02
RU2016115767A3 (cg-RX-API-DMAC7.html) 2018-06-29
AR131190A2 (es) 2025-02-26
US20160264573A1 (en) 2016-09-15
MX372585B (es) 2020-04-17
WO2015046207A1 (ja) 2015-04-02
MX367578B (es) 2019-08-27
US10000491B2 (en) 2018-06-19
JPWO2015046207A1 (ja) 2017-03-09
KR102239725B1 (ko) 2021-04-12
KR20160058851A (ko) 2016-05-25
NZ718009A (en) 2018-03-23
US10000492B2 (en) 2018-06-19
TW201546059A (zh) 2015-12-16
EP3050883B1 (en) 2020-04-22

Similar Documents

Publication Publication Date Title
TWI644908B (zh) 二氮雜二環辛烷衍生物之製法及其中間體
CN106967066B (zh) 新型β-内酰胺酶抑制剂及其制备方法
KR102487297B1 (ko) 디아자비시클로옥탄 유도체의 결정과 그의 제조법
WO2019015644A1 (zh) 肽酰胺类化合物及其制备方法和在医药上的用途
JP4486823B2 (ja) ヒドロキサム酸誘導体
HK1219473B (en) Production method for diazabicyclooctane derivative and intermediary body thereof
HK1235399B (en) Novel beta-lactamase inhibitor and process for preparing the same
HK1222651B (en) β-LACTAMASE INHIBITOR AND METHOD FOR PRODUCING THE SAME
HK1226406A1 (en) Production method for diazabicyclooctane derivatives and intermediates
HK1235399A1 (en) Novel beta-lactamase inhibitor and process for preparing the same
HK1235399A (en) Novel beta-lactamase inhibitor and process for preparing the same
HK1206746B (en) β-LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1219473

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1219473

Country of ref document: HK